Zentalis Pharmaceuticals (ZNTL) Short Interest Ratio & Short Volume → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free ZNTL Stock Alerts $11.98 +0.30 (+2.57%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Zentalis Pharmaceuticals Short Interest DataCurrent Short Volume17,500,000 sharesPrevious Short Volume16,640,000 sharesChange Vs. Previous Month+5.17%Dollar Volume Sold Short$193.55 millionShort Interest Ratio / Days to Cover21.6Last Record DateApril 30, 2024Outstanding Shares71,030,000 sharesPercentage of Shares Shorted24.64%Today's Trading Volume589,889 sharesAverage Trading Volume773,858 sharesToday's Volume Vs. Average76% Short Selling Zentalis Pharmaceuticals ? Sign up to receive the latest short interest report for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatZNTL Short Interest Over TimeZNTL Days to Cover Over TimeZNTL Percentage of Float Shorted Over Time Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company Zentalis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202417,500,000 shares $193.55 million +5.2%N/A21.6 $11.06 4/15/202416,640,000 shares $220.81 million +7.2%N/A20.4 $13.27 3/31/202415,530,000 shares $244.75 million -7.2%N/A19.1 $15.76 3/15/202416,740,000 shares $239.72 million +15.0%N/A20.3 $14.32 2/29/202414,560,000 shares $217.09 million +1.6%N/A16 $14.91 2/15/202414,330,000 shares $180.70 million +4.8%N/A17.6 $12.61 Get the Latest News and Ratings for ZNTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/202413,670,000 shares $161.99 million +4.6%N/A13.7 $11.85 1/15/202413,070,000 shares $186.38 million +2.5%N/A11.9 $14.26 12/31/202312,750,000 shares $193.16 million +10.0%N/A11.5 $15.15 12/15/202311,590,000 shares $170.03 million +4.5%N/A10.2 $14.67 11/30/202311,090,000 shares $124.76 million +4.8%N/A10.5 $11.25 11/15/202310,580,000 shares $124.00 million -5.0%N/A10.3 $11.72 10/31/202311,140,000 shares $182.25 million +4.1%N/A11.8 $16.36 10/15/202310,700,000 shares $202.66 million -5.1%N/A16.3 $18.94 9/30/202311,280,000 shares $226.28 million -0.1%N/A19.8 $20.06 9/15/202311,290,000 shares $264.30 million -5.9%N/A21.9 $23.41 8/31/202312,000,000 shares $318.72 million -3.2%N/A20.6 $26.56 8/15/202312,390,000 shares $342.46 million -7.0%N/A15.3 $27.64 7/31/202313,320,000 shares $355.78 million -2.9%N/A15.2 $26.71 7/15/202313,720,000 shares $385.81 million -5.4%N/A14.5 $28.12 6/30/202314,500,000 shares $409.05 million +9.3%N/A15 $28.21 6/15/202313,270,000 shares $368.24 million +7.9%N/A13.3 $27.75 5/31/202312,300,000 shares $320.29 million +15.8%N/A13.8 $26.04 5/15/202310,620,000 shares $297.57 million +8.0%N/A15.9 $28.02 4/30/20239,830,000 shares $216.55 million +9.1%N/A16.3 $22.03 4/15/20239,010,000 shares $164.34 million +1.2%N/A16.7 $18.24 3/31/20238,900,000 shares $153.08 million +10.2%N/A16.3 $17.20 3/15/20238,080,000 shares $147.62 million +0.9%N/A14.5 $18.27 2/28/20238,010,000 shares $151.63 million +1.3%N/A15.8 $18.93 2/15/20237,910,000 shares $161.13 million +5.3%N/A15.4 $20.37 1/31/20237,510,000 shares $177.24 million -4.6%N/A13.3 $23.60 1/15/20237,870,000 shares $196.28 million +23.6%N/A14.3 $24.94 12/30/20226,370,000 shares $128.29 million +14.6%N/A11.9 $20.14 12/15/20225,560,000 shares $107.75 million -8.1%N/A10.9 $19.38 11/30/20226,050,000 shares $133.83 million +4.7%N/A10.4 $22.12 11/15/20225,780,000 shares $132.59 million -3.0%N/A9.7 $22.94 10/31/20225,960,000 shares $149.54 million +1.4%N/A9.9 $25.09 10/15/20225,880,000 shares $135.65 million -2.0%N/A9.5 $23.07 9/30/20226,000,000 shares $129.96 million -1.2%N/A9.5 $21.66 9/15/20226,070,000 shares $154.06 million +0.3%N/A9.1 $25.38Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch his stock warning right here, 100% free of charge ZNTL Short Interest - Frequently Asked Questions What is Zentalis Pharmaceuticals' current short interest? Short interest is the volume of Zentalis Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 17,500,000 shares of ZNTL short. Learn More on Zentalis Pharmaceuticals' current short interest. What is a good short interest ratio for Zentalis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZNTL shares currently have a short interest ratio of 22.0. Learn More on Zentalis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Zentalis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Zentalis Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Zentalis Pharmaceuticals' short interest increasing or decreasing? Zentalis Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 17,500,000 shares, an increase of 5.2% from the previous total of 16,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Zentalis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Zentalis Pharmaceuticals: ALX Oncology Holdings Inc. (11.46%), 89bio, Inc. (10.93%), Praxis Precision Medicines, Inc. (5.06%), OPKO Health, Inc. (26.42%), Evolus, Inc. (9.69%), Tango Therapeutics, Inc. (19.84%), Arcutis Biotherapeutics, Inc. (18.77%), ARS Pharmaceuticals, Inc. (15.81%), ABIVAX Société Anonyme (0.12%), Pliant Therapeutics, Inc. (12.51%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Zentalis Pharmaceuticals stock? Short selling ZNTL is an investing strategy that aims to generate trading profit from Zentalis Pharmaceuticals as its price is falling. ZNTL shares are trading up $0.30 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Zentalis Pharmaceuticals? A short squeeze for Zentalis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZNTL, which in turn drives the price of the stock up even further. How often is Zentalis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZNTL, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Dianthus Therapeutics Short Interest Data Tango Therapeutics Short Interest Data Pliant Therapeutics Short Interest Data Arcturus Therapeutics Short Interest Data Evolus Short Interest Data Longboard Pharmaceuticals Short Interest Data ALX Oncology Short Interest Data ARS Pharmaceuticals Short Interest Data ABIVAX Société Anonyme Short Interest Data Disc Medicine Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ZNTL) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News